Minimization of Drug Interactions in Polypharmacy Treatments of Diabetes Mellitus Type 2 with Cardiovascular Comorbidities by Using the Decision Support Tool PM-TOM

Published: 23 February 2023| Version 1 | DOI: 10.17632/7mmz9p83bn.1
Contributors:
Adnan Kulenovic,

Description

Study: Minimization of Drug Interactions in Polypharmacy Treatments of Diabetes Mellitus Type 2 with Cardiovascular Comorbidities by Using the Decision Support Tool PM-TOM. The results of this study demonstrate that DDIs in combined polypharmacy treatments of DMT2 with its cardiovascular comorbidities can be significantly reduced by using decision support tools, like PM-TOM, while observing medical guidelines and specific patient conditions. Furthermore, the study method can be applied to any other set of DMT2 comorbidities and also to any other multi-disease. The groups of analytical treatment cases correspond to possible development stages of the considered conditions; however, they do not suggest the only ways to combine drug classes. Still, the case groups and cases analyzed in the study cover a wide set of possible treatment cases, sufficient to draw the above conclusions. This study can be used as a background for specific studies of combined polypharmacy treatments and further upgrades of the medical guidelines.

Files

Categories

Drug Receptor Interactions, Drug Adverse Reactions, Drug Treatment of Diabetes

Licence